RxDoctor Payments Data

Kimberly Smallwood, APRN

Nurse Practitioner · Sand Springs, OKNPI 1538670690

Payments from drug & device makers

$3,463in general payments, 2019–2025

Across 201 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$466
  • Novo Nordisk$465
  • Pfizer$436
  • AstraZeneca$415
  • Lilly USA, LLC$348
  • Astellas Pharma US Inc$165
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,463100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,463 in reported general payments places this provider in the 90th percentile of 824 nurse practitioner providers in Oklahoma.

See all nurse practitioner providers in Oklahoma

Medicare billing

Part B allowed, 2024
$49,924
Medicare patients
185
Services billed
2,352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide87$99,891
EliquisApixaban41$63,332
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$28,324
TradjentaLinagliptin18$17,674
MyrbetriqMirabegron17$12,135
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$9,051
XareltoRivaroxaban13$6,750
Atorvastatin Calcium271$2,626
Albuterol Sulfate HfaAlbuterol Sulfate85$2,485
Lansoprazole12$2,252
Arnuity ElliptaFluticasone Furoate11$2,179
Lisinopril279$1,854
Gabapentin107$1,806
Omeprazole135$1,560
SynthroidLevothyroxine Sodium16$1,522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$465$99,89187 claims
PfizerEliquis$436$63,33241 claims
GSKTrelegy Ellipta, Arnuity Ellipta$133$30,50348 claims
Boehringer IngelheimTradjenta$144$17,67418 claims
Astellas Pharma US IncMyrbetriq$165$12,13517 claims
AstraZenecaBreztri Aerosphere$415$9,05112 claims
Johnson & JohnsonXarelto$31$6,75013 claims
AbbVieSynthroid$66$1,52216 claims
Sanofi-aventis U.S. LLCLantus$31$1,06616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 824 nurse practitioner providers in Oklahoma.

Other nurse practitioner in Sand Springs

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →